Laura Chico
Stock Analyst at Wedbush
(3.85)
# 589
Out of 5,241 analysts
279
Total ratings
46.19%
Success rate
10.28%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Neutral | $21 → $24 | $22.98 | +4.44% | 7 | May 14, 2026 | |
| PEPG PepGen | Maintains: Outperform | $5 → $4 | $1.55 | +158.06% | 15 | May 13, 2026 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $16 | $6.92 | +131.21% | 6 | May 13, 2026 | |
| JBIO Jade Biosciences | Maintains: Outperform | $24 → $34 | $23.36 | +45.58% | 5 | May 11, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $15 → $17 | $10.80 | +57.41% | 3 | May 8, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $130 → $166 | $342.58 | -51.54% | 13 | May 8, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $27 → $26 | $25.00 | +4.00% | 17 | May 8, 2026 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $25 → $23 | $18.62 | +23.52% | 11 | May 8, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $22 → $21 | $9.02 | +132.82% | 2 | May 7, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $103 → $105 | $86.16 | +21.87% | 15 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $166 → $176 | $158.42 | +11.10% | 13 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $55 | $42.59 | +29.14% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $53 | $40.32 | +31.45% | 1 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $196 | $192.95 | +1.58% | 21 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $2.63 | +166.16% | 4 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $31 | $16.82 | +84.30% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $42 | $30.43 | +38.02% | 9 | Apr 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $3.58 | +263.13% | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $38 | $30.08 | +26.33% | 11 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $33.09 | -3.29% | 12 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $54.39 | +15.83% | 11 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 → $58 | $25.56 | +126.92% | 3 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $18 | $41.03 | -56.13% | 15 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $6 → $1 | $0.34 | +194.12% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $6.23 | +204.98% | 16 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $37.32 | -11.58% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.77 | +85.92% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $14.30 | +515.38% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $14.37 | -65.21% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $51.81 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $5.96 | -16.11% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $8.76 | +1,595.21% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $11.03 | +6,427.65% | 1 | Jan 19, 2018 |
Alto Neuroscience
May 14, 2026
Maintains: Neutral
Price Target: $21 → $24
Current: $22.98
Upside: +4.44%
PepGen
May 13, 2026
Maintains: Outperform
Price Target: $5 → $4
Current: $1.55
Upside: +158.06%
Solid Biosciences
May 13, 2026
Maintains: Outperform
Price Target: $17 → $16
Current: $6.92
Upside: +131.21%
Jade Biosciences
May 11, 2026
Maintains: Outperform
Price Target: $24 → $34
Current: $23.36
Upside: +45.58%
Climb Bio
May 8, 2026
Maintains: Outperform
Price Target: $15 → $17
Current: $10.80
Upside: +57.41%
Praxis Precision Medicines
May 8, 2026
Maintains: Underperform
Price Target: $130 → $166
Current: $342.58
Upside: -51.54%
Ultragenyx Pharmaceutical
May 8, 2026
Maintains: Neutral
Price Target: $27 → $26
Current: $25.00
Upside: +4.00%
Denali Therapeutics
May 8, 2026
Maintains: Outperform
Price Target: $25 → $23
Current: $18.62
Upside: +23.52%
BioCryst Pharmaceuticals
May 7, 2026
Maintains: Outperform
Price Target: $22 → $21
Current: $9.02
Upside: +132.82%
Dianthus Therapeutics
May 6, 2026
Maintains: Outperform
Price Target: $103 → $105
Current: $86.16
Upside: +21.87%
May 6, 2026
Maintains: Outperform
Price Target: $166 → $176
Current: $158.42
Upside: +11.10%
May 5, 2026
Maintains: Outperform
Price Target: $53 → $55
Current: $42.59
Upside: +29.14%
May 5, 2026
Initiates: Outperform
Price Target: $53
Current: $40.32
Upside: +31.45%
Apr 30, 2026
Maintains: Neutral
Price Target: $191 → $196
Current: $192.95
Upside: +1.58%
Apr 15, 2026
Reiterates: Outperform
Price Target: $7
Current: $2.63
Upside: +166.16%
Apr 8, 2026
Maintains: Outperform
Price Target: $37 → $31
Current: $16.82
Upside: +84.30%
Apr 7, 2026
Maintains: Outperform
Price Target: $41 → $42
Current: $30.43
Upside: +38.02%
Mar 20, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $3.58
Upside: +263.13%
Mar 18, 2026
Maintains: Outperform
Price Target: $36 → $38
Current: $30.08
Upside: +26.33%
Mar 17, 2026
Reiterates: Outperform
Price Target: $32
Current: $33.09
Upside: -3.29%
Mar 16, 2026
Maintains: Outperform
Price Target: $64 → $63
Current: $54.39
Upside: +15.83%
Mar 16, 2026
Maintains: Outperform
Price Target: $43 → $58
Current: $25.56
Upside: +126.92%
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $41.03
Upside: -56.13%
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.34
Upside: +194.12%
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $6.23
Upside: +204.98%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $37.32
Upside: -11.58%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.77
Upside: +85.92%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $14.30
Upside: +515.38%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $14.37
Upside: -65.21%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $51.81
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $5.96
Upside: -16.11%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $8.76
Upside: +1,595.21%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $11.03
Upside: +6,427.65%